Global Precision Oncology Market is worth USD 98.36 billion in 2023 and is estimated to grow at a CAGR of 9.9% in the forecasted period. The forecasted revenue hints at a growth of around 190.46 billion USD by 2030. Precision Oncology is increasingly essential in modern cancer care. Globally, cancer remains a leading cause of death, with an estimated 20 million new cases and 9.7 million deaths in 2022. Around 53.5 million people survived cancer within 5 years of diagnosis, but mortality rates remain concerning, with about 1 in 9 men and 1 in 12 women succumbing to the disease. Precision oncology involves analyzing tumor molecular profiles to target specific alterations and tailoring treatment plans to individual genetic characteristics. This approach, leveraging patients' genetics for personalized treatment, marks a significant advancement in cancer therapy. As precision oncology gains prominence, it is expected to play an increasingly central role in mainstream oncology practice, driven by the growing global cancer burden. Hence, the rising prevalence of cancer across the globe is anticipated to augment the need for precision oncology, thereby driving the precision oncology market growth during the forecast period.To know about the Research Methodology :- Request Free Sample Report In addition, Continuous advancements in genomic sequencing technology drive the precision oncology industry growth. The United States leads the global precision oncology market thanks to its advanced healthcare infrastructure along with substantial investments in research and development. Canada is expected to be a world leader by 2030 in the precision medicine cancer therapies sector, presumed governments ease access hurdles. The precision oncology market in Canada holds significant promise due to its advanced research infrastructure and public healthcare system. However, barriers to accessing precision therapies and biomarker testing hinder the Canadian precision oncology market size. Fragmented healthcare delivery across provinces and territories leads to unequal access to treatments, while delays in clinical trial processes impede innovation. Streamlining health systems, aligning funding with value-based care, and fostering collaboration between governments and patient groups are essential for Canada to realize its potential as a lucrative region for precision oncology advancements. Growth Drivers in Precision Oncology Market The global prevalence of cancer has risen, which has been an important driver for the market. Precision oncology offers the potential to tailor the treatments based on the unique characteristics of individual tumours, leading to improved treatment outcomes. Technologies like Immunotherapy and Gene editing have shown tremendous progression which indirectly impacted the Precision Oncology market in a positive way. The understanding of biology and molecular mechanisms behind cancer genesis and progression has considerably improved. With more information, it is now possible to identify particular genetic mutations, changes, and biomarkers that can be specifically targeted by precision oncology treatments. Thus, precision and accuracy in oncology medicines have given the market a positive boost. To support the growth and development of precision oncology market many government organisations have offered help and assistance in various researches. Example - The United States government is investing in precision oncology through a number of initiatives, including the Cancer Moonshot, the Precision Medicine Initiative, and the National Cancer Institute, while European Union government is investing in Innovative Medicines Initiative and the Horizon 2020 research program. Challenges in Precision Oncology Market The most crucial challenge for the Precision Oncology market is cost. The high cost of these technologies and treatments can limit their accessibility, particularly in resource-limited healthcare settings. Affordability and reimbursement issues present challenges for patients, healthcare systems which becomes a challenge for the market. Another concern the industry faces is regarding Data interpretation and analysis. Precision oncology generates vast amounts of complex genomic data, which requires sophisticated bioinformatics tools and expertise for interpretation. Analysing and integrating these large datasets is a significant challenge. The challenge here is not in analysing the complex data, but also in building sustainable bioinformatics tools which can simplify all this data. Also, tumours are highly heterogeneous, thus they harbour multiple genetic alterations and evolve over time, leading to treatment resistance and disease progression. Developing strategies to address tumour heterogeneity and overcome resistance mechanisms is a significant challenge in precision oncology.
Trends in Precision Oncology Market
The use of AI is going to be the most crucial phase of the precision oncology market. AI-driven tools can aid in biomarker discovery, drug development, and treatment optimization. AI can also help in simplifying the complex data at ease and also can function in analysing patterns, possible treatments, outcomes. AI powered treatment planning is assisting in predictive analysis. AI is being used to develop new algorithms that can predict how cancer cells will respond to treatment. Thus, the future of the market will depend on how AI can merge with the current market scenario. Immunotherapy has transformed cancer treatment, and ongoing research aims to enhance its efficacy and broaden its application. Combination therapies, such as combining immune checkpoint inhibitors with other targeted therapies hold promise in improving response rates. Gene editing plays a huge part in precision oncology and with advancements in the Gene editing technologies, they offer the potential to directly modify cancer-related genes and correct genetic abnormalities. Gene editing techniques can be used to develop novel therapies, enhance the effectiveness of existing treatments, and explore gene function. Thus, AI, gene editing technologies and Combination therapies will dictate the trend of the precision oncology market in the future.
Precision Oncology Market Segmentation:
Precision Oncology Market Segmentation by Product Diagnostics and Therapeutics are the 2 key segments of the precision oncology market. Therapeutics dictate nearly 70% of the segment. Therapeutics are preferred over diagnostics in the precision oncology market because they have the potential to improve patient outcomes and reduce healthcare costs. Also, treatment can effectively save a person’s life, thus therapeutics have a larger share. Therapeutics is differentiated into many branches and each field carries its own significance. Precision Oncology Market Segmentation by Cancer Types Breast Cancer is the most common type of cancer and accounts for nearly 41% of this segment. Cervical cancer has the highest CAGR amongst the five and is expected to grow in the forecasted period. Prostate Cancer and Lung Cancer share nearly equal market. Early diagnosis helps in Precise oncology medicines and thus identification is very important. Colorectal cancer has least market amongst all the five types.Precision Oncology Market by End User Diagnostics laboratories accounts for the largest market share which is around 47%, followed by pharma companies who have been investing lately into the market as the future seems to be bright of such markets. Healthcare data companies have huge future but in current scenario they lack enough of a market share.
Precision Oncology Market Regional Insights
Precision Oncology Market: Global The market is filled with small and big companies. US has dominated the market and holds nearly 44% of the market. Globally, the precision oncology market has seen huge development especially after 2010. The reason has been technological advancements, huge investments and progressive research into this field. Precision Oncology Market: North America North America enjoys the highest share of the market, which mainly consist of USA. The strong market presence of key players like Illumina, Thermo Fisher Scientific has made it sure that the market leader remains the same. The region has advanced laboratory facilities, cutting-edge technologies, and a strong ecosystem of clinicians, researchers, and industry players. Its application use has been one of the best which has helped them sustain the market force. Next-generation sequencing (NGS) technologies, which are essential to precision oncology, were first used in North America. Comprehensive genomic profiling and the detection of useful genetic changes in cancer patients are made possible by NGS. Canada and Mexico have smaller market share as compared to US but are emerging markets in market. Precision Oncology Market: Asia Pacific Asia Pacific has been a growing market, especially after huge investments into the market. China, Japan, India have emerged as leaders in the market. According to the World Health Organization, China had an estimated 3.9 million new cancer cases and 2.3 million cancer deaths in 2023. Thus, China has huge market share of the industry. Increase in population and increase in patients both have made sure that the precision oncology market increase in Asia Pacific Precision Oncology Market: Europe Europe has been a traditional market for precision oncology. Developed countries like UK and Germany have made huge technological progress which have helped the market grow and sustain in a competitive environment. The growing adoption of molecular diagnostics is expected to drive the growth of the market in Europe. European Union has also invested heavily into the market which has made Europe a dominant force into research. Cancer is one of the leading causes of death in Switzerland, which is an emerging market in the oncology market. Precision Oncology Market: Middle East and Africa Middle East and Africa does not have a huge market share. There has been focus on developing a research environment especially in Saudi Arabia and UAE. The Saudi government launched the Saudi National Precision Medicine Strategy to accelerate the development and application of precision medicine in Saudi Arabia. The major players in the Saudi Arabia precision oncology market are Roche, Novartis, Pfizer, AstraZeneca, and Merck. These companies are investing in research and development to develop new precision oncology products. They are also expanding their geographic reach to tap into the growing market opportunities in Saudi Arabia Precision Oncology Market: South America South America is an emerging market. Brazil has a well-established pharmaceutical and biotechnology industry, supported by strong research and development capabilities. Argentina has focused on innovation, research and development, and quality manufacturing process. Columbia has been investing in healthcare from past decade, which gives it an opportunity to have similar market share as of that of Brazil and Argentina. Other countries like Peru, Chile are also slowly gaining a higher market share.Precision Oncology Market: Competitive Landscape
The precision oncology market has seen huge growth, especially after increase in oncological studies. The market has seen a positive growth and many emerging markets like India and Japan have made sure that the market diversifies. North America is the market leader as US has nearly 44% of market share due to heavy infrastructural investments. Top companies like Pfizer, Johnson & Johnson have made sure that US holds onto that market share. Europe has 2nd highest market share after US and countries like UK (AstraZeneca), Germany (Merck) and Switzerland (Roche) have made sure that the precision oncology market progresses in Europe. Asia Pacific has shown the highest market growth and is expected to rise in future.
Precision Oncology Market Scope: Inquire before buying
Precision Oncology Market Report Coverage Details Base Year: 2023 Forecast Period: 2024-2030 Historical Data: 2018 to 2023 Market Size in 2023: US $ 98.36 Bn. Forecast Period 2024 to 2030 CAGR: 9.9% Market Size in 2030: US $ 190.46 Bn. Segments Covered: by Products Diagnostics Therapeutics by Cancer Types Breast Cancer Lung Cancer Cervical cancer Colorectal Cancer Prostate Cancer by End User Pharmaceutical & Biotechnology Companies Diagnostic Centres Healthcare Data Companies Precision Oncology Market, by Region
North America (United States, Canada and Mexico) Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe) Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC) Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A) South America (Brazil, Argentina Rest of South America)Precision Oncology Market: Key Players
The players mentioned are top companies working in Precision Oncology Market. All these companies have shown tremendous strategy and have huge potential to maximize the Precision Oncology Market. 1. Illumina, Inc. (United States) 2. Thermo Fisher Scientific, Inc. (United States) 3. Agilent Technologies, Inc. (United States) 4. Invitae Corporation (United States) 5. NeoGenomics Laboratories, Inc. (United States) 6. Bristol Myers Squibb Company (United States) 7. Pfizer Inc. (United States) 8. Amgen Inc. (United States) 9. Merck & Co., Inc. (United States) 10. Eli Lilly and Company (United States) 11. Genomic Health, Inc. (United States) 12. Foundation Medicine, Inc. (United States) 13. Guardant Health, Inc. (United States) 14. Myriad Genetics, Inc. (United States) 15. Exact Sciences Corporation (United States) 16. NanoString Technologies, Inc. (United States) 17. Guardant Health, Inc. (United States) 18. F. Hoffmann-La Roche Ltd (Switzerland) 19. Bayer AG (Germany) 20. AstraZeneca plc (United Kingdom) 21. Novartis AG (Switzerland) 22. Roche Holding AG (Switzerland) 23. Qiagen N.V. (Netherlands) 24. Sysmex Corporation (Japan) 25. Dasa (Brazil) FAQ Q.1) What is the CAGR of market? Ans: The CAGR for market is 9.9%. Q.2) Which are the leading companies in market? Ans: Thermo Fischer and Merck are some of the leading companies in the market. Q.3) Which region shows maximum potential in market Ans: Asia Pacific is expected to grow exponentially and is likely to dominate market in future. Q,4) Which is the leading region in market? Ans: North America leads the market of market significantly. Q.5) What was the forecasted period of this report? Ans: The forecasted period for the market research was 2024 – 2030.
1. Precision Oncology Market Introduction 1.1. Study Assumption and Market Definition 1.2. Scope of the Study 1.3. Executive Summary 2. Precision Oncology Market: Dynamics 2.1. Precision Oncology Market Trends by Region 2.1.1. North America Precision Oncology Market Trends 2.1.2. Europe Precision Oncology Market Trends 2.1.3. Asia Pacific Precision Oncology Market Trends 2.1.4. Middle East and Africa Precision Oncology Market Trends 2.1.5. South America Precision Oncology Market Trends 2.2. Precision Oncology Market Dynamics by Region 2.2.1. North America 2.2.1.1. North America Precision Oncology Market Drivers 2.2.1.2. North America Precision Oncology Market Restraints 2.2.1.3. North America Precision Oncology Market Opportunities 2.2.1.4. North America Precision Oncology Market Challenges 2.2.2. Europe 2.2.2.1. Europe Precision Oncology Market Drivers 2.2.2.2. Europe Precision Oncology Market Restraints 2.2.2.3. Europe Precision Oncology Market Opportunities 2.2.2.4. Europe Precision Oncology Market Challenges 2.2.3. Asia Pacific 2.2.3.1. Asia Pacific Precision Oncology Market Drivers 2.2.3.2. Asia Pacific Precision Oncology Market Restraints 2.2.3.3. Asia Pacific Precision Oncology Market Opportunities 2.2.3.4. Asia Pacific Precision Oncology Market Challenges 2.2.4. Middle East and Africa 2.2.4.1. Middle East and Africa Precision Oncology Market Drivers 2.2.4.2. Middle East and Africa Precision Oncology Market Restraints 2.2.4.3. Middle East and Africa Precision Oncology Market Opportunities 2.2.4.4. Middle East and Africa Precision Oncology Market Challenges 2.2.5. South America 2.2.5.1. South America Precision Oncology Market Drivers 2.2.5.2. South America Precision Oncology Market Restraints 2.2.5.3. South America Precision Oncology Market Opportunities 2.2.5.4. South America Precision Oncology Market Challenges 2.3. PORTER’s Five Forces Analysis 2.4. PESTLE Analysis 2.5. Technology Roadmap 2.6. Regulatory Landscape by Region 2.6.1. North America 2.6.2. Europe 2.6.3. Asia Pacific 2.6.4. Middle East and Africa 2.6.5. South America 2.7. Key Opinion Leader Analysis For Precision Oncology Industry 2.8. Analysis of Government Schemes and Initiatives For Precision Oncology Industry 2.9. Precision Oncology Market Trade Analysis 2.10. The Global Pandemic Impact on Precision Oncology Market 3. Precision Oncology Market: Global Market Size and Forecast by Segmentation by Demand and Supply Side (by Value in USD Million) 2023-2030 3.1. Precision Oncology Market Size and Forecast, by Product (2023-2030) 3.1.1. Diagnostics 3.1.2. Therapeutics 3.2. Precision Oncology Market Size and Forecast, by Cancer Type (2023-2030) 3.2.1. Breast Cancer 3.2.2. Lung Cancer 3.2.3. Cervical cancer 3.2.4. Colorectal Cancer 3.2.5. Prostate Cancer 3.3. Precision Oncology Market Size and Forecast, by End User (2023-2030) 3.3.1. Pharmaceutical & Biotechnology Companies 3.3.2. Diagnostic Centres 3.3.3. Healthcare Data Companies 3.4. Precision Oncology Market Size and Forecast, by Region (2023-2030) 3.4.1. North America 3.4.2. Europe 3.4.3. Asia Pacific 3.4.4. Middle East and Africa 3.4.5. South America 4. North America Precision Oncology Market Size and Forecast by Segmentation (by Value in USD Million) 2023-2030 4.1. North America Precision Oncology Market Size and Forecast, by Product (2023-2030) 4.1.1. Diagnostics 4.1.2. Therapeutics 4.2. North America Precision Oncology Market Size and Forecast, by Cancer Type (2023-2030) 4.2.1. Breast Cancer 4.2.2. Lung Cancer 4.2.3. Cervical cancer 4.2.4. Colorectal Cancer 4.2.5. Prostate Cancer 4.3. North America Precision Oncology Market Size and Forecast, by End User (2023-2030) 4.3.1. Pharmaceutical & Biotechnology Companies 4.3.2. Diagnostic Centres 4.3.3. Healthcare Data Companies 4.4. North America Precision Oncology Market Size and Forecast, by Country (2023-2030) 4.4.1. United States 4.4.1.1. United States Precision Oncology Market Size and Forecast, by Product (2023-2030) 4.4.1.1.1. Diagnostics 4.4.1.1.2. Therapeutics 4.4.1.2. United States Precision Oncology Market Size and Forecast, by Cancer Type (2023-2030) 4.4.1.2.1. Breast Cancer 4.4.1.2.2. Lung Cancer 4.4.1.2.3. Cervical cancer 4.4.1.2.4. Colorectal Cancer 4.4.1.2.5. Prostate Cancer 4.4.1.3. United States Precision Oncology Market Size and Forecast, by End User (2023-2030) 4.4.1.3.1. Pharmaceutical & Biotechnology Companies 4.4.1.3.2. Diagnostic Centres 4.4.1.3.3. Healthcare Data Companies 4.4.2. Canada 4.4.2.1. Canada Precision Oncology Market Size and Forecast, by Product (2023-2030) 4.4.2.1.1. Diagnostics 4.4.2.1.2. Therapeutics 4.4.2.2. Canada Precision Oncology Market Size and Forecast, by Cancer Type (2023-2030) 4.4.2.2.1. Breast Cancer 4.4.2.2.2. Lung Cancer 4.4.2.2.3. Cervical cancer 4.4.2.2.4. Colorectal Cancer 4.4.2.2.5. Prostate Cancer 4.4.2.3. Canada Precision Oncology Market Size and Forecast, by End User (2023-2030) 4.4.2.3.1. Pharmaceutical & Biotechnology Companies 4.4.2.3.2. Diagnostic Centres 4.4.2.3.3. Healthcare Data Companies 4.4.3. Mexico 4.4.3.1. Mexico Precision Oncology Market Size and Forecast, by Product (2023-2030) 4.4.3.1.1. Diagnostics 4.4.3.1.2. Therapeutics 4.4.3.2. Mexico Precision Oncology Market Size and Forecast, by Cancer Type (2023-2030) 4.4.3.2.1. Breast Cancer 4.4.3.2.2. Lung Cancer 4.4.3.2.3. Cervical cancer 4.4.3.2.4. Colorectal Cancer 4.4.3.2.5. Prostate Cancer 4.4.3.3. Mexico Precision Oncology Market Size and Forecast, by End User (2023-2030) 4.4.3.3.1. Pharmaceutical & Biotechnology Companies 4.4.3.3.2. Diagnostic Centres 4.4.3.3.3. Healthcare Data Companies 5. Europe Precision Oncology Market Size and Forecast by Segmentation (by Value in USD Million) 2023-2030 5.1. Europe Precision Oncology Market Size and Forecast, by Product (2023-2030) 5.2. Europe Precision Oncology Market Size and Forecast, by Cancer Type (2023-2030) 5.3. Europe Precision Oncology Market Size and Forecast, by End User (2023-2030) 5.4. Europe Precision Oncology Market Size and Forecast, by Country (2023-2030) 5.4.1. United Kingdom 5.4.1.1. United Kingdom Precision Oncology Market Size and Forecast, by Product (2023-2030) 5.4.1.2. United Kingdom Precision Oncology Market Size and Forecast, by Cancer Type (2023-2030) 5.4.1.3. United Kingdom Precision Oncology Market Size and Forecast, by End User (2023-2030) 5.4.2. France 5.4.2.1. France Precision Oncology Market Size and Forecast, by Product (2023-2030) 5.4.2.2. France Precision Oncology Market Size and Forecast, by Cancer Type (2023-2030) 5.4.2.3. France Precision Oncology Market Size and Forecast, by End User (2023-2030) 5.4.3. Germany 5.4.3.1. Germany Precision Oncology Market Size and Forecast, by Product (2023-2030) 5.4.3.2. Germany Precision Oncology Market Size and Forecast, by Cancer Type (2023-2030) 5.4.3.3. Germany Precision Oncology Market Size and Forecast, by End User (2023-2030) 5.4.4. Italy 5.4.4.1. Italy Precision Oncology Market Size and Forecast, by Product (2023-2030) 5.4.4.2. Italy Precision Oncology Market Size and Forecast, by Cancer Type (2023-2030) 5.4.4.3. Italy Precision Oncology Market Size and Forecast, by End User (2023-2030) 5.4.5. Spain 5.4.5.1. Spain Precision Oncology Market Size and Forecast, by Product (2023-2030) 5.4.5.2. Spain Precision Oncology Market Size and Forecast, by Cancer Type (2023-2030) 5.4.5.3. Spain Precision Oncology Market Size and Forecast, by End User (2023-2030) 5.4.6. Sweden 5.4.6.1. Sweden Precision Oncology Market Size and Forecast, by Product (2023-2030) 5.4.6.2. Sweden Precision Oncology Market Size and Forecast, by Cancer Type (2023-2030) 5.4.6.3. Sweden Precision Oncology Market Size and Forecast, by End User (2023-2030) 5.4.7. Austria 5.4.7.1. Austria Precision Oncology Market Size and Forecast, by Product (2023-2030) 5.4.7.2. Austria Precision Oncology Market Size and Forecast, by Cancer Type (2023-2030) 5.4.7.3. Austria Precision Oncology Market Size and Forecast, by End User (2023-2030) 5.4.8. Rest of Europe 5.4.8.1. Rest of Europe Precision Oncology Market Size and Forecast, by Product (2023-2030) 5.4.8.2. Rest of Europe Precision Oncology Market Size and Forecast, by Cancer Type (2023-2030) 5.4.8.3. Rest of Europe Precision Oncology Market Size and Forecast, by End User (2023-2030) 6. Asia Pacific Precision Oncology Market Size and Forecast by Segmentation (by Value in USD Million) 2023-2030 6.1. Asia Pacific Precision Oncology Market Size and Forecast, by Product (2023-2030) 6.2. Asia Pacific Precision Oncology Market Size and Forecast, by Cancer Type (2023-2030) 6.3. Asia Pacific Precision Oncology Market Size and Forecast, by End User (2023-2030) 6.4. Asia Pacific Precision Oncology Market Size and Forecast, by Country (2023-2030) 6.4.1. China 6.4.1.1. China Precision Oncology Market Size and Forecast, by Product (2023-2030) 6.4.1.2. China Precision Oncology Market Size and Forecast, by Cancer Type (2023-2030) 6.4.1.3. China Precision Oncology Market Size and Forecast, by End User (2023-2030) 6.4.2. S Korea 6.4.2.1. S Korea Precision Oncology Market Size and Forecast, by Product (2023-2030) 6.4.2.2. S Korea Precision Oncology Market Size and Forecast, by Cancer Type (2023-2030) 6.4.2.3. S Korea Precision Oncology Market Size and Forecast, by End User (2023-2030) 6.4.3. Japan 6.4.3.1. Japan Precision Oncology Market Size and Forecast, by Product (2023-2030) 6.4.3.2. Japan Precision Oncology Market Size and Forecast, by Cancer Type (2023-2030) 6.4.3.3. Japan Precision Oncology Market Size and Forecast, by End User (2023-2030) 6.4.4. India 6.4.4.1. India Precision Oncology Market Size and Forecast, by Product (2023-2030) 6.4.4.2. India Precision Oncology Market Size and Forecast, by Cancer Type (2023-2030) 6.4.4.3. India Precision Oncology Market Size and Forecast, by End User (2023-2030) 6.4.5. Australia 6.4.5.1. Australia Precision Oncology Market Size and Forecast, by Product (2023-2030) 6.4.5.2. Australia Precision Oncology Market Size and Forecast, by Cancer Type (2023-2030) 6.4.5.3. Australia Precision Oncology Market Size and Forecast, by End User (2023-2030) 6.4.6. Indonesia 6.4.6.1. Indonesia Precision Oncology Market Size and Forecast, by Product (2023-2030) 6.4.6.2. Indonesia Precision Oncology Market Size and Forecast, by Cancer Type (2023-2030) 6.4.6.3. Indonesia Precision Oncology Market Size and Forecast, by End User (2023-2030) 6.4.7. Malaysia 6.4.7.1. Malaysia Precision Oncology Market Size and Forecast, by Product (2023-2030) 6.4.7.2. Malaysia Precision Oncology Market Size and Forecast, by Cancer Type (2023-2030) 6.4.7.3. Malaysia Precision Oncology Market Size and Forecast, by End User (2023-2030) 6.4.8. Vietnam 6.4.8.1. Vietnam Precision Oncology Market Size and Forecast, by Product (2023-2030) 6.4.8.2. Vietnam Precision Oncology Market Size and Forecast, by Cancer Type (2023-2030) 6.4.8.3. Vietnam Precision Oncology Market Size and Forecast, by End User (2023-2030) 6.4.9. Taiwan 6.4.9.1. Taiwan Precision Oncology Market Size and Forecast, by Product (2023-2030) 6.4.9.2. Taiwan Precision Oncology Market Size and Forecast, by Cancer Type (2023-2030) 6.4.9.3. Taiwan Precision Oncology Market Size and Forecast, by End User (2023-2030) 6.4.10. Rest of Asia Pacific 6.4.10.1. Rest of Asia Pacific Precision Oncology Market Size and Forecast, by Product (2023-2030) 6.4.10.2. Rest of Asia Pacific Precision Oncology Market Size and Forecast, by Cancer Type (2023-2030) 6.4.10.3. Rest of Asia Pacific Precision Oncology Market Size and Forecast, by End User (2023-2030) 7. Middle East and Africa Precision Oncology Market Size and Forecast by Segmentation (by Value in USD Million) 2023-2030 7.1. Middle East and Africa Precision Oncology Market Size and Forecast, by Product (2023-2030) 7.2. Middle East and Africa Precision Oncology Market Size and Forecast, by Cancer Type (2023-2030) 7.3. Middle East and Africa Precision Oncology Market Size and Forecast, by End User (2023-2030) 7.4. Middle East and Africa Precision Oncology Market Size and Forecast, by Country (2023-2030) 7.4.1. South Africa 7.4.1.1. South Africa Precision Oncology Market Size and Forecast, by Product (2023-2030) 7.4.1.2. South Africa Precision Oncology Market Size and Forecast, by Cancer Type (2023-2030) 7.4.1.3. South Africa Precision Oncology Market Size and Forecast, by End User (2023-2030) 7.4.2. GCC 7.4.2.1. GCC Precision Oncology Market Size and Forecast, by Product (2023-2030) 7.4.2.2. GCC Precision Oncology Market Size and Forecast, by Cancer Type (2023-2030) 7.4.2.3. GCC Precision Oncology Market Size and Forecast, by End User (2023-2030) 7.4.3. Nigeria 7.4.3.1. Nigeria Precision Oncology Market Size and Forecast, by Product (2023-2030) 7.4.3.2. Nigeria Precision Oncology Market Size and Forecast, by Cancer Type (2023-2030) 7.4.3.3. Nigeria Precision Oncology Market Size and Forecast, by End User (2023-2030) 7.4.4. Rest of ME&A 7.4.4.1. Rest of ME&A Precision Oncology Market Size and Forecast, by Product (2023-2030) 7.4.4.2. Rest of ME&A Precision Oncology Market Size and Forecast, by Cancer Type (2023-2030) 7.4.4.3. Rest of ME&A Precision Oncology Market Size and Forecast, by End User (2023-2030) 8. South America Precision Oncology Market Size and Forecast by Segmentation (by Value in USD Million) 2023-2030 8.1. South America Precision Oncology Market Size and Forecast, by Product (2023-2030) 8.2. South America Precision Oncology Market Size and Forecast, by Cancer Type (2023-2030) 8.3. South America Precision Oncology Market Size and Forecast, by End User(2023-2030) 8.4. South America Precision Oncology Market Size and Forecast, by Country (2023-2030) 8.4.1. Brazil 8.4.1.1. Brazil Precision Oncology Market Size and Forecast, by Product (2023-2030) 8.4.1.2. Brazil Precision Oncology Market Size and Forecast, by Cancer Type (2023-2030) 8.4.1.3. Brazil Precision Oncology Market Size and Forecast, by End User (2023-2030) 8.4.2. Argentina 8.4.2.1. Argentina Precision Oncology Market Size and Forecast, by Product (2023-2030) 8.4.2.2. Argentina Precision Oncology Market Size and Forecast, by Cancer Type (2023-2030) 8.4.2.3. Argentina Precision Oncology Market Size and Forecast, by End User (2023-2030) 8.4.3. Rest Of South America 8.4.3.1. Rest Of South America Precision Oncology Market Size and Forecast, by Product (2023-2030) 8.4.3.2. Rest Of South America Precision Oncology Market Size and Forecast, by Cancer Type (2023-2030) 8.4.3.3. Rest Of South America Precision Oncology Market Size and Forecast, by End User (2023-2030) 9. Global Precision Oncology Market: Competitive Landscape 9.1. MMR Competition Matrix 9.2. Competitive Landscape 9.3. Key Players Benchmarking 9.3.1. Company Name 9.3.2. Business Segment 9.3.3. End-user Segment 9.3.4. Revenue (2022) 9.3.5. Company Locations 9.4. Leading Precision Oncology Market Companies, by market capitalization 9.5. Market Structure 9.5.1. Market Leaders 9.5.2. Market Followers 9.5.3. Emerging Players 9.6. Mergers and Acquisitions Details 10. Company Profile: Key Players 10.1. Illumina, Inc. (United States) 10.1.1. Company Overview 10.1.2. Business Portfolio 10.1.3. Financial Overview 10.1.4. SWOT Analysis 10.1.5. Strategic Analysis 10.1.6. Scale of Operation (small, medium, and large) 10.1.7. Details on Partnership 10.1.8. Regulatory Accreditations and Certifications Received by Them 10.1.9. Awards Received by the Firm 10.1.10. Recent Developments 10.2. Thermo Fisher Scientific, Inc. (United States) 10.3. Agilent Technologies, Inc. (United States) 10.4. Invitae Corporation (United States) 10.5. NeoGenomics Laboratories, Inc. (United States) 10.6. Bristol Myers Squibb Company (United States) 10.7. Pfizer Inc. (United States) 10.8. Amgen Inc. (United States) 10.9. Merck & Co., Inc. (United States) 10.10. Eli Lilly and Company (United States) 10.11. Genomic Health, Inc. (United States) 10.12. Foundation Medicine, Inc. (United States) 10.13. Guardant Health, Inc. (United States) 10.14. Myriad Genetics, Inc. (United States) 10.15. Exact Sciences Corporation (United States) 10.16. NanoString Technologies, Inc. (United States) 10.17. Guardant Health, Inc. (United States) 10.18. F. Hoffmann-La Roche Ltd (Switzerland) 10.19. Bayer AG (Germany) 10.20. AstraZeneca plc (United Kingdom) 10.21. Novartis AG (Switzerland) 10.22. Roche Holding AG (Switzerland) 10.23. Qiagen N.V. (Netherlands) 10.24. Sysmex Corporation (Japan) 10.25. Dasa (Brazil) 11. Key Findings 12. Industry Recommendations 13. Precision Oncology Market: Research Methodology 14. Terms and Glossary